Evaluation of the diagnostic efficacy of serum DR-70 and its combination with CEA in lung cancer.

IF 1.9 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Biomarkers in medicine Pub Date : 2025-07-01 Epub Date: 2025-07-11 DOI:10.1080/17520363.2025.2525071

Xuena Wang, Xianda Wei, Zifeng Cheng, Xu Zhou, Xiaoyun Lei, Wen Zhao, Qiuxing Tao, Zhilüe Lü, Hua Lin, Baoheng Gui

{"title":"Evaluation of the diagnostic efficacy of serum DR-70 and its combination with CEA in lung cancer.","authors":"Xuena Wang, Xianda Wei, Zifeng Cheng, Xu Zhou, Xiaoyun Lei, Wen Zhao, Qiuxing Tao, Zhilüe Lü, Hua Lin, Baoheng Gui","doi":"10.1080/17520363.2025.2525071","DOIUrl":null,"url":null,"abstract":"Objective: To evaluate the diagnostic value of DR-70 immunoassay and its combination with carcinoembryonic antigen (CEA) measurement for detecting lung malignancies.Methods: Serum concentrations of carcinoembryonic antigen (CEA) and DR-70 were quantitatively assessed using electrochemiluminescence immunoassay (ECLIA) and enzyme-linked immunosorbent assay (ELISA), in 110 patients diagnosed with primary lung cancer, 48 patients with pulmonary benign lesions, and 164 healthy subjects.Results: Serum levels of both DR-70 and CEA showed statistically significant differences between lung cancer patients and healthy controls (p < 0.001). The study found that the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and area under the curve (AUC), for DR-70 alone were 71.8%, 84.2%, 70.5%, 85.7%, and 0.836, respectively, which was superior to the values of 62.7%, 68.3%, 49.6%, 78.6%, 0.689 for CEA alone. The values for the combination of DR-70 and CEA were 87.3, 55.7%, 50.0%, 89.8%, and 0.846. The combination method significantly improved the sensitivity, NPV and AUC while concurrently reducing specificity and PPV, compared to DR-70 or CEA alone.Conclusion: Individual serum DR-70 testing and the combined DR-70+CEA panel exhibited robust diagnostic efficacy in lung adenocarcinoma detection.","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":"19 14","pages":"605-611"},"PeriodicalIF":1.9000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers in medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17520363.2025.2525071","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/11 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To evaluate the diagnostic value of DR-70 immunoassay and its combination with carcinoembryonic antigen (CEA) measurement for detecting lung malignancies.

Methods: Serum concentrations of carcinoembryonic antigen (CEA) and DR-70 were quantitatively assessed using electrochemiluminescence immunoassay (ECLIA) and enzyme-linked immunosorbent assay (ELISA), in 110 patients diagnosed with primary lung cancer, 48 patients with pulmonary benign lesions, and 164 healthy subjects.

Results: Serum levels of both DR-70 and CEA showed statistically significant differences between lung cancer patients and healthy controls (p < 0.001). The study found that the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and area under the curve (AUC), for DR-70 alone were 71.8%, 84.2%, 70.5%, 85.7%, and 0.836, respectively, which was superior to the values of 62.7%, 68.3%, 49.6%, 78.6%, 0.689 for CEA alone. The values for the combination of DR-70 and CEA were 87.3, 55.7%, 50.0%, 89.8%, and 0.846. The combination method significantly improved the sensitivity, NPV and AUC while concurrently reducing specificity and PPV, compared to DR-70 or CEA alone.

Conclusion: Individual serum DR-70 testing and the combined DR-70+CEA panel exhibited robust diagnostic efficacy in lung adenocarcinoma detection.

查看原文本刊更多论文

血清DR-70及其联合CEA对肺癌的诊断价值评价。

目的：探讨DR-70免疫分析法及其联合癌胚抗原（CEA）检测对肺部恶性肿瘤的诊断价值。方法：采用电化学发光免疫分析法（ECLIA）和酶联免疫吸附法（ELISA）定量测定110例原发性肺癌患者、48例肺部良性病变患者和164例正常人的血清癌胚抗原（CEA）和DR-70浓度。结果：血清DR-70和CEA水平在肺癌患者与健康对照组之间均有统计学差异(p)。结论：单个血清DR-70检测和DR-70+CEA联合检测在肺腺癌诊断中具有较强的疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biomarkers in medicine 医学-医学：研究与实验

CiteScore

3.80

自引率

4.50%

发文量

审稿时长

6-12 weeks

期刊介绍： Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory. Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice. As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications. Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest. Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.